Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era
Grazia Arpino(University of Naples Federico II), Sabino De Placido, Carmine De Angelis(Baylor College of Medicine), Cinzia Cardalesi(University of Naples Federico II), Emma Montella(Federico II University Hospital), Roberto Bianco(Federico II University Hospital), Luigi Formisano(University of Naples Federico II), Valeria Forestieri(University of Naples Federico II), Mario Giuliano(Regione Campania), Giovanni Fiore(University of Naples Federico II), Rossella Lauria, Erica Pietroluongo(University of Naples Federico II), Anna Iervolino(University of Campania "Luigi Vanvitelli"), Emilia Anna Vozzella(Federico II University Hospital), Pietro De Placido(University of Naples Federico II)
Cited by 15
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
|Endocrine Reviews|2008|545
A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models
|Cancer Research|2013|485
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials
|Journal of Clinical Oncology|2007|413
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
|Cancer Treatment Reviews|2018|282